Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007 - PubMed (original) (raw)
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
Alexander M Walker et al. Pharmacoepidemiol Drug Saf. 2008 Aug.
Abstract
Background: The risk of coronary heart disease (CHD) in users of antidiabetic agents must be quantified to permit reasoned therapeutic choices.
Objectives: To assess the risk of myocardial infarction (MI) and coronary revascularization (CR), in diabetic patients who began rosiglitazone, pioglitazone, metformin, or sulfonylureas.
Methods: We conducted a retrospective cohort study of MI and CR in the PharMetrics database. We performed head-to-head comparisons using propensity-score-stratified Cox proportional hazards models, examining risks both on-treatment and during total follow-up before regimen switches.
Results: For the combined outcome (MI and CR), the crude rates per 1000 person years were 9 on monotherapy, 13 on dual therapy, and 21 on therapies combined with insulin. In the absence of insulin, regimens containing thiazolidinediones (TZDs) tended toward lower risk than comparable regimens containing sulfonylureas and higher risk than those containing metformin. The summary hazard ratio for rosiglitazone versus pioglitazone was 1.04 (95%CI: 0.94-1.14) for total follow-up and 1.05 (0.92-1.19) for on-treatment time. For MI, the hazard ratios were 1.07 (0.89-1.27) for total follow-up and 1.21 (0.95-1.54) for on-treatment time.
Conclusions: The present data indicate that the risk of CHD in patients using TZDs appears to lie between the risks associated with sulfonylureas and metformin. Neither the risk of MI and CR together nor the risk of MI alone was significantly different between rosiglitazone and pioglitazone. A nonsignificant observed excess risk of 21% for MI during on-treatment time will require combination with the results of other studies to provide a reliable assessment.
Comment in
- Cardiac safety of diabetes therapies and postmarketing requirements.
Faich GA, Stemhagen A. Faich GA, et al. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):787-9. doi: 10.1002/pds.1622. Pharmacoepidemiol Drug Saf. 2008. PMID: 18655015 No abstract available. - The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Califf RM, Kramer JM. Califf RM, et al. Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):782-6. doi: 10.1002/pds.1617. Pharmacoepidemiol Drug Saf. 2008. PMID: 18655016 No abstract available.
Similar articles
- The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K. Ziyadeh N, et al. Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003. Clin Ther. 2009. PMID: 20110009 - Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. McAfee AT, et al. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25. doi: 10.1002/pds.1443. Pharmacoepidemiol Drug Saf. 2007. PMID: 17551989 - The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. Johannes CB, et al. Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12. doi: 10.1002/pds.1356. Pharmacoepidemiol Drug Saf. 2007. PMID: 17245800 - Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U, Pop-Busui R, Eagle KA. Khanderia U, et al. Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18698014 Review. - Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A. Krentz A. Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Diabetes Metab Res Rev. 2009. PMID: 19219860 Review.
Cited by
- The forgotten type 2 diabetes mellitus medicine: rosiglitazone.
Xu B, Xing A, Li S. Xu B, et al. Diabetol Int. 2021 Jun 29;13(1):49-65. doi: 10.1007/s13340-021-00519-0. eCollection 2022 Jan. Diabetol Int. 2021. PMID: 35059243 Free PMC article. Review. - Healthcare Databases for Drug Safety Research: Data Validity Assessment Remains Crucial.
Rawson NSB, D'Arcy C. Rawson NSB, et al. Drug Saf. 2018 Sep;41(9):829-833. doi: 10.1007/s40264-018-0673-z. Drug Saf. 2018. PMID: 29714003 Review. - Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool.
Bilandzic A, Fitzpatrick T, Rosella L, Henry D. Bilandzic A, et al. PLoS Med. 2016 Apr 5;13(4):e1001987. doi: 10.1371/journal.pmed.1001987. eCollection 2016 Apr. PLoS Med. 2016. PMID: 27046153 Free PMC article. - Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Pladevall M, et al. BMC Cardiovasc Disord. 2016 Jan 15;16:14. doi: 10.1186/s12872-016-0187-5. BMC Cardiovasc Disord. 2016. PMID: 26769243 Free PMC article. - Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.
Patorno E, Patrick AR, Garry EM, Schneeweiss S, Gillet VG, Bartels DB, Masso-Gonzalez E, Seeger JD. Patorno E, et al. Diabetologia. 2014 Nov;57(11):2237-50. doi: 10.1007/s00125-014-3364-z. Epub 2014 Sep 12. Diabetologia. 2014. PMID: 25212258 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical